The U.S. Food and Drug Administration has accepted Intarcia Therapeutics' New Drug Application for ITCA 650, which can be used to treat Type 2 diabetes.
ITCA 650 is being examined for application through a continuous delivery system, known as an osmotic mini-pump that would be positioned directly under the skin in the abdominal wall and would deliver exenatide.
In the studies leading up to the submission of the new treatment, patients were given 20 mcg/day for a three-month introductory period and then were given 60 mcg/day for a six-month maintenance dose.
Intarcia is a biopharmaceutical company that seeks to create drug therapies that are continuous and effective. This new application would allow Intarcia to use its technology of the Medici Drug Delivery System.
Intarcia's application for Type 2 diabetes treatment is accepted
Alerts Sign-up